Bruker Corporation research snapshot
BRKR AI stock analysis currently reads Bruker as a specialized scientific instruments company with meaningful positions in magnetic resonance, mass spectrometry, microscopy, spatial biology, semiconductor metrology, and superconducting technologies. FY2025 revenue increased 2.1% to $3.44 billion, but organic revenue declined 3.7%, free cash flow fell to $43.3 million, and GAAP earnings were hurt by impairment and restructuring charges. Bruker reaffirmed FY2026 revenue guidance of $3.57 billion to $3.60 billion and non-GAAP EPS guidance of $2.10 to $2.15 after Q1 revenue rose 2.7% year over year. At the July 10, 2026 close near $60.06, the BRKR AI stock forecast is a scenario exercise rather than a fixed price prediction. This page is for informational use only and is not investment advice.
Current price
$60.06 at the July 10, 2026 close
Market cap
$9.14 billion calculated from 152.23 million shares, versus about $9.14 billion reported
AI score
61 / 100
Rating
Scientific instruments franchise with recovery potential, but execution and valuation risk
Trend status
Above the 20-day, 50-day, and 200-day moving averages with positive but not overbought momentum
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bruker sells complex research and analytical instruments used in life science, materials, semiconductor, industrial, and security applications. | High |
| Moat | Technology depth, installed workflows, application expertise, brand, service, and customer switching friction support the moat, although some product categories face strong competition. | Medium-high |
| Management | Frank H. Laukien has led Bruker since February 1991 and is its largest stockholder, aligning long-term ownership with the business while increasing key-person and governance concentration risk. | High |
| Financial trend | FY2025 revenue rose 2.1%, but organic revenue declined 3.7%, GAAP operating income fell to $68.2 million, and free cash flow dropped to $43.3 million. | High |
| Valuation | At $60.06, BRKR is about 26.7x the midpoint of FY2026 non-GAAP EPS guidance, 2.64x sales, and 3.73x book value, while FY2025 GAAP EPS and free cash flow were weak. | High |
| Technical trend | The stock is above the 5-day average near $59.49, 20-day average near $58.26, 50-day average near $51.78, and 200-day average near $43.80, with RSI near 58. | Medium |
| Risk level | The largest risks are weaker academic and industrial demand, China and tariff pressure, acquisition execution, debt service, impairment, foreign exchange, and key-person concentration. | High |
| AI confidence | Descriptive data confidence is high because company filings and independent market data align. Return confidence is lower because normalized earnings and cash conversion are still being rebuilt. | High data confidence |
| Investment certainty | The business is understandable and technically differentiated, but the current price requires successful FY2026 execution and leaves limited room for another earnings reset. | Medium |
BRKR AI stock forecast
The BRKR AI stock forecast uses the FY2026 non-GAAP EPS guidance midpoint of $2.125 as a normalized starting point. A three-year model using 15%, 8%, and negative 5% annual EPS growth with 32x, 27x, and 22x exit multiples produced mechanical values of about $103.4, $72.3, and $40.1. These are scenario outputs, not guaranteed targets, and they exclude dividends and future dilution.
$98 to $108
More likely if BSI bookings convert into organic growth, AI-related semiconductor metrology demand stays strong, academic funding improves, acquisitions add earnings without balance-sheet strain, and margins recover toward historical levels.
$68 to $76
More likely if FY2026 guidance is achieved, organic growth returns gradually, non-GAAP EPS grows near high single digits over three years, and the market keeps a high-twenties earnings multiple on the recovery case.
$37 to $43
More likely if academic and industrial budgets remain weak, China and tariff pressure deepen, acquisitions underperform, free cash flow stays near 2025 levels, or the market reduces the multiple toward the low twenties.
BRKR AI technical analysis
BRKR AI technical analysis is constructive as of the July 10, 2026 close. The price is above the 5-day, 20-day, 50-day, and 200-day moving averages, and StockAnalysis reports RSI near 58. The stock has also gained 42.59% over 52 weeks, so momentum is positive but the risk of a crowded recovery trade should be monitored.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $60.06 | StockAnalysis and MarketBeat reported the regular-market close on July 10, 2026. |
| Immediate support | $57.20 to $58.30 | The July 7 and July 8 closing range is the first short-term demand zone. |
| Secondary support | $54.20 to $55.20 | Recent June and July closes clustered in this area before the latest rebound. |
| Near resistance | $61.60 to $63.10 | The July 1 and July 2 highs and closes define the next recovery test. |
| Major resistance | $64.50 to $66.00 | The June 4 high near $64.54 and the prior trading range form a wider supply zone. |
| Moving averages | 5-day $59.49, 20-day $58.26, 50-day $51.78, 200-day $43.80 | The 5-day and 20-day figures are calculated from StockAnalysis daily closes. The 50-day and 200-day figures are from its July 2026 statistics snapshot. |
| Momentum | RSI 57.96, positive but not overbought | The RSI reading is near the upper half of the neutral range. A move above resistance needs volume and earnings confirmation. |
| Volume and volatility | 2.24M average shares, beta 1.29, 52-week change +42.59% | StockAnalysis statistics as checked on July 12, 2026. Price volatility is higher than the broad market reference. |
| Invalidation | Daily close below $51.78 | A sustained break below the 50-day average would weaken the current recovery setup and require a new fundamental review. |
BRKR AI trading strategy
The BRKR AI trading strategy below is a rules-based research framework, not personal advice. It combines price confirmation with bookings, organic revenue, academic budgets, semiconductor demand, cash conversion, leverage, and acquisition execution.
Watch for BRKR to hold above the $61.60 to $63.10 resistance area while quarterly results confirm improving organic growth, BSI book-to-bill above 1.0x, and a recovery in non-GAAP operating margin.
A failed breakout followed by a close below $58.26 reduces short-term confidence. A close below $51.78 invalidates the medium-term trend setup.
If BRKR pulls back toward $57.20 to $58.30 without a guidance cut, compare the price move with bookings, academic funding, China demand, currency effects, and the progress of cost savings.
Do not average down solely because the stock is below a recent high. Avoid treating a low price-to-sales ratio as protection if free cash flow and operating margins continue to deteriorate.
Track BSI bookings and book-to-bill, organic revenue, gross and operating margin, FY2026 EPS guidance, free cash flow, cash and debt, acquisition contribution, impairment charges, insider ownership, and China exposure.
Position sizing should reflect integration risk, debt service, currency swings, public research funding, tariff changes, product acceptance, and concentrated ownership.
Investment research summary
Bruker sells high-performance scientific instruments and analytical solutions. Customers pay for measurement accuracy, reliability, application support, workflow compatibility, and the ability to answer difficult questions in biology, chemistry, materials, semiconductors, and diagnostics.
The moat is strongest in technical know-how, proprietary instrument design, installed workflows, application libraries, service relationships, and a global specialist sales network. Switching costs rise when laboratories validate methods, train staff, and build datasets around a platform. Network effects are limited, so the moat must be renewed through product development and customer success.
The thesis fails if government and academic budgets weaken, industrial customers delay capital spending, China and tariff pressures reduce demand, acquisitions require more restructuring, impairment charges recur, debt service absorbs cash, or new products fail to gain adoption. The 2025 organic decline and free cash flow drop show that a high-quality product portfolio does not remove cycle risk.
Frank H. Laukien has served as Bruker chairman, president, and CEO since February 1991 and is the largest stockholder. Long tenure and meaningful ownership can support patient investment, but they also create key-person and governance concentration risk. The current capital-allocation test is whether acquisitions, research spending, and cost savings can restore cash returns without adding excessive leverage or dilution.
Bruker participates in durable trends including structural biology, multiomics, spatial biology, advanced materials, semiconductor process control, diagnostics, and security detection. These are long-term scientific and industrial needs, but revenue timing depends on government grants, pharmaceutical research budgets, semiconductor capital spending, currency, geopolitics, and customer financing.
At about 26.7x the midpoint of FY2026 non-GAAP EPS guidance and 2.64x sales, BRKR is priced for a recovery rather than distress. FY2025 GAAP EPS was negative and free cash flow per share was about $0.29, so the margin of safety depends on guidance delivery, operating-margin recovery, better cash conversion, and disciplined acquisition spending.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BRKR closing price | $60.06 on July 10, 2026 | StockAnalysis and MarketBeat | July 12, 2026 |
| Shares outstanding | 152.23 million current shares; 152.14 million common shares at December 31, 2025 | StockAnalysis statistics and Bruker 2025 Annual Report | July 12, 2026 |
| Market capitalization verification | $9.14 billion from $60.06 x 152.23 million shares; 0.03% deviation from reported $9.14 billion | Pineify financial_rigor.py and StockAnalysis statistics | July 12, 2026 |
| FY2025 revenue | $3.4365 billion in the annual report and $3.437 billion in StockAnalysis and Macrotrends | Bruker 2025 Annual Report, StockAnalysis, and Macrotrends | July 12, 2026 |
| FY2025 net income attributable to common shareholders | Loss of $22.5 million, consistent across the annual report and StockAnalysis | Bruker 2025 Annual Report and StockAnalysis financials | July 12, 2026 |
| FY2025 free cash flow | $43.3 million, or about $0.29 per share, down from $136.0 million in 2024 | Bruker full-year 2025 results and Macrotrends | July 12, 2026 |
| Q1 2026 operating results | $823.4 million revenue, up 2.7% year over year, with $47.0 million free cash flow | Bruker Q1 2026 Financial Results | July 12, 2026 |
| FY2026 guidance | $3.57 billion to $3.60 billion revenue and $2.10 to $2.15 non-GAAP EPS | Bruker Q1 2026 Financial Results | July 12, 2026 |
| Cash and debt | $133.4 million cash and $1.71 billion debt at the latest reported quarter | Bruker Q1 2026 Financial Results and StockAnalysis statistics | July 12, 2026 |
| Technical snapshot | 50-day average $51.78, 200-day average $43.80, RSI 57.96, average volume 2.24 million, beta 1.29 | StockAnalysis statistics | July 12, 2026 |
| Management and ownership | Frank H. Laukien has led Bruker since February 1991; StockAnalysis reports insider ownership of 31.89% | Bruker corporate governance and StockAnalysis statistics | July 12, 2026 |
This BRKR AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a solicitation to buy or sell securities. Forecast scenarios are based on available public data as of July 12, 2026 and can be wrong if earnings, research budgets, tariffs, currency, acquisition execution, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
